Device Tech Transfer: A Tale of Two Programs
This article was originally published in Start Up
Executive Summary
Though the very basis of the biotech industry, university technology transfer in medical devices has largely been ignored. The difficulty behind device tech transfer: innovation occurs differently in devices than in biotech. New device designs are frequently the result of sudden realizations by physicians, rather than extensive clinical discovery. Stanford University and Germany's Steinbeis Center are implementing different approaches, evolving out of their respective environments, but aimed at achieving the same goal: promoting device technology transfer.
You may also be interested in...
Embolic Protection: Better Outcomes Not Enough
For 20 years, interventional cardiologists denied the need for embolic protection devices, considering embolic events to generally be the infrequent results of poor technique. Nevertheless, recent data has revealed embolization as a potentially serious and relatively common event during percutaneous coronary interventions. While embolic protection devices have been shown to dramatically reduce embolic complications, physician adoption is slow. Several companies are developing different approaches to protect against embolization, recognizing that better patient data alone isn't enough to convince interventionalists to employ these devices.
US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month
Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.